BDNF levels used as a biomarker for AD diagnosis and progressivity follow-up might have a limitation in its specificity because changes in BDNF, as previously described, also occur in several other neurodegenerative and neurobehavior diseases, although not as significant as in AD. This evidence concerns the gene BDNF and Alzheimer disease.